Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
361
Recruiting Now
361
Top Conditions in Phase 1 / Phase 2
NCT06712680 Phase 1, Phase 2
Recruiting
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and...
Condition
Solid Tumor
Enrollment
115 pts
Location
China
Sponsor
Sichuan Huiyu Pharmaceutical C
NCT06088654 Phase 1, Phase 2
Recruiting
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgk...
Condition
Non Hodgkin Lymphoma
Enrollment
184 pts
Location
United States, Australia, France
Sponsor
Innate Pharma
NCT04753970 Phase 1, Phase 2
Recruiting
Retina is a Marker for Cerebrovascular Heath
Condition
Cerebral Small Vessel Diseases
Enrollment
100 pts
Location
United States
Sponsor
Mayo Clinic
NCT07047703 Phase 1, Phase 2
Recruiting
EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)
Condition
Axial Spondyloarthritis (AxSpA)
Enrollment
141 pts
Location
Australia, Belgium, Germany
Sponsor
Grey Wolf Therapeutics
NCT06719596 Phase 1, Phase 2
Recruiting
Probiotics Combined with Enteral Nutrition Reduces Postoperative Infectious Comp...
Condition
Infectious Complications
Enrollment
68 pts
Location
China
Sponsor
The Affiliated Nanjing Drum To
NCT06819215 Phase 1, Phase 2
Recruiting
Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced ...
Condition
Cancer
Enrollment
188 pts
Location
China
Sponsor
Zhejiang Yangli Pharmaceutical
NCT04982276 Phase 1, Phase 2
Recruiting
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophagea...
Condition
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Enrollment
138 pts
Location
China
Sponsor
Akeso
NCT06887803 Phase 1, Phase 2
Recruiting
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofib...
Condition
Myelofibrosis (MF)
Enrollment
26 pts
Location
Italy, Spain
Sponsor
iOnctura
NCT04396899 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human My...
Condition
Heart Failure
Enrollment
53 pts
Location
Germany
Sponsor
University Medical Center Goet
NCT05807932 Phase 1, Phase 2
Recruiting
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine /...
Condition
Myelodysplastic Syndromes
Enrollment
38 pts
Location
Germany
Sponsor
Heinrich-Heine University, Due
NCT06650332 Phase 1, Phase 2
Recruiting
Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/G...
Condition
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Enrollment
90 pts
Location
China
Sponsor
Zhejiang Cancer Hospital
NCT07203599 Phase 1, Phase 2
Recruiting
A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Co...
Condition
Androgenic Alopecia
Enrollment
59 pts
Location
China
Sponsor
Shenzhen People's Hospital
NCT06244992 Phase 1, Phase 2
Recruiting
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic ...
Condition
Locally Advanced or Metastatic Solid Tumors
Enrollment
68 pts
Location
United States
Sponsor
Pyrotech Therapeutics, Inc.
NCT06827236 Phase 1, Phase 2
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called...
Condition
Locally Advanced Breast Cancer
Enrollment
380 pts
Location
United States, Canada, China
Sponsor
BioNTech SE
NCT05634369 Phase 1, Phase 2
Recruiting
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK...
Condition
Pediatric Sarcoma, Refractory
Enrollment
50 pts
Location
United States
Sponsor
Nationwide Children's Hospital
NCT05689853 Phase 1, Phase 2
Recruiting
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Condition
Solid Tumor, Adult
Enrollment
87 pts
Location
China
Sponsor
Akeso
NCT02843945 Phase 1, Phase 2
Recruiting
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With ...
Condition
Pancreatic Cancer
Enrollment
80 pts
Location
United States
Sponsor
CivaTech Oncology
NCT06611839 Phase 1, Phase 2
Recruiting
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed ID...
Condition
AML
Enrollment
29 pts
Location
China
Sponsor
Institute of Hematology & Bloo
NCT05053971 Phase 1, Phase 2
Recruiting
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanc...
Condition
Advanced Malignant Solid Neoplasm
Enrollment
49 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT06572813 Phase 1, Phase 2
Recruiting
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Canc...
Condition
Pancreas Cancer
Enrollment
63 pts
Location
China
Sponsor
Zhejiang University
NCT07012954 Phase 1, Phase 2
Recruiting
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wi...
Condition
Colorectal Cancer Metastatic
Enrollment
64 pts
Location
China
Sponsor
Sun Yat-sen University
NCT07359066 Phase 1, Phase 2
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Stu...
Condition
Advanced Solid Tumors
Enrollment
210 pts
Location
China
Sponsor
Shanghai SciBrunch Therapeutic
NCT05394103 Phase 1, Phase 2
Recruiting
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Condition
Advanced Cancer
Enrollment
130 pts
Location
United States, South Korea
Sponsor
Qurient Co., Ltd.
NCT07382531 Phase 1, Phase 2
Recruiting
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Condition
Solid Tumor
Enrollment
30 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co.,
NCT06526819 Phase 1, Phase 2
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
Condition
Solid Tumor
Enrollment
120 pts
Location
United States, Japan
Sponsor
Sumitomo Pharma America, Inc.